Cargando…

Effects of venlafaxine on gastrointestinal symptoms, depression, anxiety, stress, and quality of life in patients with the moderate-to-severe irritable bowel syndrome

BACKGROUND: Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder which its treatment is still a question. According to the literature, the use of antidepressants is common for IBS, while its efficacy in this regard is controversial. This study has been raised to assess the...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharbafchi, Mohammad Reza, Afshar, Hamid, Adhamian, Pardis, Feizi, Awat, Daghaghzadeh, Hamed, Adibi, Peyman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067890/
https://www.ncbi.nlm.nih.gov/pubmed/33912225
http://dx.doi.org/10.4103/jrms.JRMS_699_19
_version_ 1783682908259614720
author Sharbafchi, Mohammad Reza
Afshar, Hamid
Adhamian, Pardis
Feizi, Awat
Daghaghzadeh, Hamed
Adibi, Peyman
author_facet Sharbafchi, Mohammad Reza
Afshar, Hamid
Adhamian, Pardis
Feizi, Awat
Daghaghzadeh, Hamed
Adibi, Peyman
author_sort Sharbafchi, Mohammad Reza
collection PubMed
description BACKGROUND: Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder which its treatment is still a question. According to the literature, the use of antidepressants is common for IBS, while its efficacy in this regard is controversial. This study has been raised to assess the efficacy of venlafaxine in IBS patients. MATERIALS AND METHODS: In this double-blind, randomized clinical trial, 33 patients with moderate-to-severe IBS were included and randomly divided into two groups by using permuted block randomization process of size 4 for each block to receive Venlafaxine or placebo. Venlafaxine in 37.5 mg/day for 2 weeks, followed by 75 mg/day for the next 2 weeks and then 150 mg/day until the end of the study was prescribed. Gastrointestinal symptoms severity, depression, anxiety, stress as main, and quality of life (QoL) as the secondary outcomes were evaluated at the study initiation, within 2, 6, and 12 weeks after treatment and 3 months after intervention cessation. RESULTS: The gastrointestinal symptoms severity, depression, anxiety, stress, and QoL scores significantly improved in patients who received Venlafaxine but not in placebo group; although after treatment discontinuation they experienced relapse (P < 0.05). Patients treated with venlafaxine experienced significant improvement in IBS symptoms, all three psychological disorders and QoL than placebo group (P < 0.01). The frequency of observed side effects in venlafaxine group including vomiting, nausea, and sleep disturbance was higher than placebo. CONCLUSION: Venlafaxine could be considered as an effective treatment for improving gastrointestinal symptoms severity, depression, anxiety, stress, and QoL of patients with IBS. Further studies with larger sample size and longer treatment duration are recommended.
format Online
Article
Text
id pubmed-8067890
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-80678902021-04-27 Effects of venlafaxine on gastrointestinal symptoms, depression, anxiety, stress, and quality of life in patients with the moderate-to-severe irritable bowel syndrome Sharbafchi, Mohammad Reza Afshar, Hamid Adhamian, Pardis Feizi, Awat Daghaghzadeh, Hamed Adibi, Peyman J Res Med Sci Original Article BACKGROUND: Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder which its treatment is still a question. According to the literature, the use of antidepressants is common for IBS, while its efficacy in this regard is controversial. This study has been raised to assess the efficacy of venlafaxine in IBS patients. MATERIALS AND METHODS: In this double-blind, randomized clinical trial, 33 patients with moderate-to-severe IBS were included and randomly divided into two groups by using permuted block randomization process of size 4 for each block to receive Venlafaxine or placebo. Venlafaxine in 37.5 mg/day for 2 weeks, followed by 75 mg/day for the next 2 weeks and then 150 mg/day until the end of the study was prescribed. Gastrointestinal symptoms severity, depression, anxiety, stress as main, and quality of life (QoL) as the secondary outcomes were evaluated at the study initiation, within 2, 6, and 12 weeks after treatment and 3 months after intervention cessation. RESULTS: The gastrointestinal symptoms severity, depression, anxiety, stress, and QoL scores significantly improved in patients who received Venlafaxine but not in placebo group; although after treatment discontinuation they experienced relapse (P < 0.05). Patients treated with venlafaxine experienced significant improvement in IBS symptoms, all three psychological disorders and QoL than placebo group (P < 0.01). The frequency of observed side effects in venlafaxine group including vomiting, nausea, and sleep disturbance was higher than placebo. CONCLUSION: Venlafaxine could be considered as an effective treatment for improving gastrointestinal symptoms severity, depression, anxiety, stress, and QoL of patients with IBS. Further studies with larger sample size and longer treatment duration are recommended. Wolters Kluwer - Medknow 2020-12-30 /pmc/articles/PMC8067890/ /pubmed/33912225 http://dx.doi.org/10.4103/jrms.JRMS_699_19 Text en Copyright: © 2020 Journal of Research in Medical Sciences https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Sharbafchi, Mohammad Reza
Afshar, Hamid
Adhamian, Pardis
Feizi, Awat
Daghaghzadeh, Hamed
Adibi, Peyman
Effects of venlafaxine on gastrointestinal symptoms, depression, anxiety, stress, and quality of life in patients with the moderate-to-severe irritable bowel syndrome
title Effects of venlafaxine on gastrointestinal symptoms, depression, anxiety, stress, and quality of life in patients with the moderate-to-severe irritable bowel syndrome
title_full Effects of venlafaxine on gastrointestinal symptoms, depression, anxiety, stress, and quality of life in patients with the moderate-to-severe irritable bowel syndrome
title_fullStr Effects of venlafaxine on gastrointestinal symptoms, depression, anxiety, stress, and quality of life in patients with the moderate-to-severe irritable bowel syndrome
title_full_unstemmed Effects of venlafaxine on gastrointestinal symptoms, depression, anxiety, stress, and quality of life in patients with the moderate-to-severe irritable bowel syndrome
title_short Effects of venlafaxine on gastrointestinal symptoms, depression, anxiety, stress, and quality of life in patients with the moderate-to-severe irritable bowel syndrome
title_sort effects of venlafaxine on gastrointestinal symptoms, depression, anxiety, stress, and quality of life in patients with the moderate-to-severe irritable bowel syndrome
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067890/
https://www.ncbi.nlm.nih.gov/pubmed/33912225
http://dx.doi.org/10.4103/jrms.JRMS_699_19
work_keys_str_mv AT sharbafchimohammadreza effectsofvenlafaxineongastrointestinalsymptomsdepressionanxietystressandqualityoflifeinpatientswiththemoderatetosevereirritablebowelsyndrome
AT afsharhamid effectsofvenlafaxineongastrointestinalsymptomsdepressionanxietystressandqualityoflifeinpatientswiththemoderatetosevereirritablebowelsyndrome
AT adhamianpardis effectsofvenlafaxineongastrointestinalsymptomsdepressionanxietystressandqualityoflifeinpatientswiththemoderatetosevereirritablebowelsyndrome
AT feiziawat effectsofvenlafaxineongastrointestinalsymptomsdepressionanxietystressandqualityoflifeinpatientswiththemoderatetosevereirritablebowelsyndrome
AT daghaghzadehhamed effectsofvenlafaxineongastrointestinalsymptomsdepressionanxietystressandqualityoflifeinpatientswiththemoderatetosevereirritablebowelsyndrome
AT adibipeyman effectsofvenlafaxineongastrointestinalsymptomsdepressionanxietystressandqualityoflifeinpatientswiththemoderatetosevereirritablebowelsyndrome